Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.55 |
| ▸ | RIPK2 | O43353 | 11/20 | 0.51 |
| ▸ | ABL1 | P00519 | 6/20 | 0.50 |
| ▸ | EGFR | P00533 | 6/20 | 0.50 |
| ▸ | ABL2 | P42684 | 6/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | SIK1 | P57059 | 1/20 | 0.45 |
| ▸ | RIPK4 | P57078 | 1/20 | 0.45 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | DSTYK | Q6XUX3 | 1/20 | 0.45 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30813428 | 1.00 | SRC (0.55) | SRCRIPK2ABL1EGFRABL2 | |
| SCHEMBL27217772 | 0.85 | SRC (0.57) | SRCRIPK2ABL1EGFRABL2 | |
| SCHEMBL30813385 | 0.85 | SRC (0.57) | SRCRIPK2ABL1EGFRABL2 | |
| SCHEMBL30813394 | 0.81 | SRC (0.58) | SRCRIPK2ABL1EGFRABL2 | |
| SCHEMBL27217867 | 0.81 | SRC (0.58) | SRCRIPK2ABL1EGFRABL2 | |
| SCHEMBL23966913 | 0.75 | SRC (0.73) | SRCRIPK2ABL1EGFRABL2 | |
| SCHEMBL20351628 | 0.71 | SRC (0.80) | SRCRIPK2ABL1EGFRABL2 | |
| SCHEMBL23966729 | 0.71 | SRC (0.63) | SRCRIPK2ABL1EGFRABL2 | |
| SCHEMBL30180884 | 0.71 | SRC (0.63) | SRCRIPK2ABL1EGFRABL2 | |
| SCHEMBL23966720 | 0.71 | SRC (0.70) | SRCRIPK2ABL1EGFRABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | SRC 1597/4885RIPK2 45/4885ABL1 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.